tirzepatide micro dose Microdosing Tirzepatide: How It Works, Benefits & Timeline Tirzepatide Micro-Dose Program | Weight

The study used once weekly semaglutide dosed at 2.4 mg

Results at 68 weeks: 40.4% of CagriSema participants lost 25% or more of their body weight 91.9% lost at least 5% Blood pressure fell by 10.9 mmHg systolic on average About 40% of participants reduced or stopped blood pressure medications 87.7% of those with prediabetes at baseline achieved normal blood sugar Results were published in the New England Journal of Medicine and presented at the American Diabetes Associations 2026 Scientific Sessions

Some patients experience improved nutrient absorption as they stabilize on semaglutide and develop a sustainable eating pattern with adequate protein and whole foods

When ASCVD predominates: ASCVD is considered to predominate if a patient has established ASCVD or if they have indicators of high ASCVD risk